• FDA clears IND application for cancer therapeutic IMT-009

    1 day ago - By Healio

    FDA cleared an investigational new drug application for IMT-009, a fully human monoclonal antibody that combats inhibitory T-cell target CD161, according to a company press release.
    The IND clearance applies to patients who are refractory to standard-of-care therapy, or ineligible for or refused another existing treatment option.
    The clearance of IMT-009 indicates the continuation of recent developments of cell therapy in cancer treatment.
    “We are thrilled to advance IMT-009 to the clinic as we believe it represents a new wave of immuno-oncology agents with
    Read more ...